Clinically employed screening tests based on angiogenesis-related biomarkers (eg, soluble fms-like tyrosine kinase 1 [sFlt-1] and placental growth factor [PlGF]) are able to predict the onset of preeclampsia only a few weeks before presentation of clinically obvious preeclampsia (7). The gene discussed is FLT1; the disease is preeclampsia.